Published in Cancer Weekly, March 6th, 2007
HepaLife announced that in ongoing research, scientists have demonstrated that the Company's patented PICM-19 cells have unique characteristics distinct from other cells, and are able to successfully mimic the human liver's response in several important ways. Among other research outcomes, important liver specific activity levels in the PICM-19 cells were up to three times higher than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.